3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Neoplasms
5
Lung Neoplasms
3
Anxiety Disorders
3
Solitary Pulmonary Nodule
2
Paresthesia
2
Multiple Pulmonary Nodules
2
Hypesthesia
2
Dyspnea
2
Depression
2
Brain Neoplasms
2
Surgical Wound Infection
1
Skin Neoplasms
1
Radiation Injuries
1
Pulmonary Atelectasis
1
Prostatic Neoplasms
1
Prostatic Hyperplasia
1
Prostatic Diseases
1
Postoperative Complications
1
Pain
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Leukemia
1
Inflammatory Bowel Diseases
1
Hypoxia
1
Hematologic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Tea
3
Polyethylene Glycols
3
Infliximab
3
MEDI2070
2
Lidocaine
2
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
2
sodium phosphate
1
prucalopride
1
polyethylene glycol 400
1
picosulfate sodium
1
golimumab
1
cabozantinib
1
Surgical Tape
1
Standard of Care
1
Spectrum Analysis, Raman
1
Specimen Handling
1
Pneumococcal Vaccines
1
Platinum Compounds
1
Passive Cutaneous Anaphylaxis
1
Papillomavirus Vaccines
1
Oxygen
1
Nivolumab
1
Neomycin
1
Narrow Band Imaging
1
Morphine
1
Metronidazole
1
Medical Marijuana
1
Laparoscopy
1
Ipilimumab
1
Indocyanine Green
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Inflammatory Bowel Diseases
×
Oxygen
×
Clear all
NCT06109961
2023-11-07
HYPNOTIC
Ottawa Hospital Research Institute
Phase 1/2
Unknown
40 enrolled